NImmune Biopharma (NYSE:ABBV) presented Phase 1 and preclinical data at Digestive Disease Week 2026 showing that oral, once-daily NIM-1324 met primary and secondary endpoints, engaged the LANCL2 target, showed improved PK, and had a favorable safety profile with no dose-limiting toxicities.
The program advances a LANCL2 immunometabolic mechanism for ulcerative colitis and Crohn’s disease and supports a well-powered Phase 2 testing 125, 250, and 1000 mg doses versus placebo.
NImmune Biopharma will present preclinical and translational data on LANCL2-targeting therapeutics at IMMUNOLOGY2026 (April 15–19, 2026). Data show oral NIM-1324 and topical omilancor outperforming current psoriasis treatments in multiple mouse models, first-in-human NIM-1324 met primary and secondary endpoints, and NIM-1324 is Phase 2-ready for ulcerative colitis and other indications.
Findings highlight LANCL2-driven Treg enhancement, reduced pro-inflammatory mediators, improved phagocyte clearance, and translational blood signatures supporting target engagement.
AbbVie has completed its acquisition of Landos Biopharma, enhancing its portfolio with NX-13, a first-in-class oral NLRX1 agonist currently in Phase 2 trials for treating ulcerative colitis (UC) and Crohn's disease (CD). The acquisition, priced at $20.42 per share plus up to $11.14 per share upon achieving a clinical milestone, aims to offer a novel, dual-action treatment approach to inflammatory bowel disease (IBD), combining anti-inflammatory properties and epithelial repair. Landos' stock will stop trading on NASDAQ from May 24, 2024. AbbVie expressed its commitment to transforming the standard of care for IBD patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.